Cancer treatment-induced bone loss

Area of Science:

• Oncology
• Endocrinology
• Bone Metabolism

Background:

• Cancer treatments can induce bone loss, increasing osteoporosis and fracture risk in patients.
• Specific patient groups, including childhood cancer survivors and those with hypogonadal cancer treatment, are particularly vulnerable.
• Emerging therapies like aromatase inhibitors may exacerbate bone loss compared to alternatives like tamoxifen.

Purpose of the Study:

• To guide clinicians in identifying, evaluating, and managing cancer treatment-induced bone loss.
• To highlight the importance of proactive bone health assessment in cancer patients.
• To review current strategies for mitigating fracture risk in this population.

Main Methods:

• This is a review article synthesizing current evidence on cancer treatment-induced bone loss.
• The review focuses on identifying at-risk populations and evaluating management strategies.
• Literature search on osteoporosis, fracture risk, and treatment interventions in cancer patients was conducted.

Main Results:

• Patients treated for breast and prostate cancer, especially those with treatment-induced hypogonadism, are at significant risk.
• Aromatase inhibitors are associated with increased osteoporosis risk compared to tamoxifen.
• Bisphosphonates have demonstrated efficacy in preventing bone loss in at-risk cancer patients.

Conclusions:

• Calcium, vitamin D, and bisphosphonate therapy can effectively reduce fractures in cancer patients.
• Management of cancer treatment-induced bone loss is crucial for improving patient outcomes.
• Clinicians should implement systematic bone health evaluations for at-risk cancer patients.